|
Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase
|
Rattus norvegicus
|
369.0
nM
|
|
Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase
|
Rattus norvegicus
|
543.0
nM
|
|
|
Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM
|
Rattus norvegicus
|
62.0
%
|
|
|
Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes
|
Rattus norvegicus
|
786.0
nM
|
|
|
In vitro antifungal activity against Aspergillus fumigatus
|
Aspergillus fumigatus
|
100.0
%
|
|
|
In vitro antifungal activity against Candida albicans
|
Candida albicans
|
100.0
%
|
|
|
In vitro antifungal activity against Candida tropicalis
|
Candida tropicalis
|
10.0
%
|
|
|
Inhibition of Corticoid 11-beta-hydroxylase cytochrome P450
|
Bos taurus
|
608.0
nM
|
|
Inhibition of Corticoid 11-beta-hydroxylase cytochrome P450
|
Bos taurus
|
152.0
nM
|
|
|
Inhibition of cytochrome P450 Cholesterol 7-alpha-hydroxylase
|
Rattus norvegicus
|
195.0
nM
|
|
|
Evaluated for the inhibitory activity towards Cytochrome P450 17 human enzyme using testicular microsome at 25 uM of substrate (progesterone)
|
None
|
740.0
nM
|
|
|
Tested for inhibitory activity against Cytochrome P450 17 from human testicular microsomes
|
None
|
740.0
nM
|
|
|
Inhibition of human testicular microsomal Cytochrome P450 17A1
|
Homo sapiens
|
78.0
nM
|
|
|
Inhibition of human testicular microsomal Cytochrome P450 17A1
|
Homo sapiens
|
77.0
nM
|
|
|
Binding affinity for Cytochrome P450 17A1 (17-alpha-hydroxypregnenolone Km=560 nM)
|
Homo sapiens
|
38.0
nM
|
|
|
Inhibition of rat Cytochrome P450 17A1
|
Rattus norvegicus
|
209.0
nM
|
|
|
Ability to inhibit the C17,20-lyase enzyme by 50% using 17-alpha-hydroxyprogesterone as substrate.
|
None
|
26.0
nM
|
|
|
Inhibition of human testicular 17-alpha-hydroxylase
|
None
|
920.0
nM
|
|
|
Tested for inhibition of human testicular C17,20-Lyase.
|
None
|
26.0
nM
|
|
|
Inhibition of 17-alpha-hydroxylase enzyme, cytochrome P450 17A1 of human testicular microsomes
|
Homo sapiens
|
65.0
nM
|
|
|
Inhibition of C17,20-lyase enzyme, cytochrome P450 17A1 in Human testicular microsomes
|
Homo sapiens
|
26.0
nM
|
|
|
Inhibition of human testicular microsomal cytochrome P450 17A1
|
Homo sapiens
|
67.0
%
|
|
|
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes
|
Homo sapiens
|
13.0
nM
|
|
|
Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes
|
Homo sapiens
|
17.0
nM
|
|
|
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes
|
Homo sapiens
|
22.0
nM
|
|
|
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes
|
Homo sapiens
|
16.0
nM
|
|
|
In vitro antifungal activity against Cryptococcus neoformans
|
Cryptococcus neoformans
|
10.0
%
|
|
|
Inhibition of human cytochrome P450 3A4
|
None
|
50.0
nM
|
|
|
Inhibition of lanosterol 14 alpha-demethylase cytochrome P450 51A
|
Rattus norvegicus
|
119.0
nM
|
|
Inhibition of lanosterol 14 alpha-demethylase cytochrome P450 51A
|
Rattus norvegicus
|
47.0
nM
|
|
|
Inhibition of cellular cholesterol biosynthesis using human fibroblasts in tissue culture
|
Homo sapiens
|
37.0
nM
|
|
|
Dissociation constant was determined in vitro using rat pituitary membranes and [125I]leuprolide as radioligand, at concentration 3.16*10e-5 M
|
Rattus norvegicus
|
811.0
nM
|
|
|
Dissociation constant was determined in vitro using rat pituitary membranes and [125I]-leuprolide as radioligand, at concentration 3.16*10e-6 M
|
Rattus norvegicus
|
0.221
nM
|
|
|
Dissociation constant was determined in vitro using rat pituitary membranes, at concentration 1.0*10e-5 M
|
Rattus norvegicus
|
0.375
nM
|
|
|
In vitro antifungal activity against Microsporum canis
|
Arthroderma otae
|
100.0
%
|
|
|
In vivo inhibitory activity against A-23187 ear edema at a dose of 100 ug/ear
|
Mus musculus
|
8.0
%
|
|
|
In vivo inhibitory activity against arachidonic acid(AA) ear edema at a dose of 100 ug/ear
|
Mus musculus
|
10.0
%
|
|
|
In vitro antifungal activity against Mucor sp
|
Mucor
|
100.0
%
|
|
|
Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells
|
None
|
35.0
%
|
|
|
In vitro antifungal activity against Phialophora verrucosa
|
Phialophora verrucosa
|
10.0
%
|
|
|
In vitro antifungal activity against Saprolegnia sp
|
Saprolegnia
|
10.0
%
|
|
|
In vitro antifungal activity against Sporothrix schenck ii
|
Sporothrix schenckii
|
10.0
%
|
|
|
Ability to inhibit the Steroid 17-alpha-hydroxylase/17,20 lyase enzyme by 50%.
|
None
|
65.0
nM
|
|
|
Inhibition of human testicular steroid 17-alpha-hydroxylase
|
None
|
860.0
nM
|
|
|
Inhibition of human testicular microsome Steroid 17-alpha-hydroxylase/17,20 lyase
|
Homo sapiens
|
740.0
nM
|
|
|
Tested for inhibition of human testicular Steroid 17-alpha-hydroxylase/17,20 lyase
|
None
|
65.0
nM
|
|
|
Inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase cytochrome P450 17A1
|
Sus scrofa
|
50.0
nM
|
|
|
Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase from rat testes microsomes at 100 uM
|
Rattus norvegicus
|
48.0
%
|
|
|
Growth inhibitory activity against Trypanosoma cruzi (Epimastigote)
|
Trypanosoma cruzi
|
1.7
ug.mL-1
|
|
|
In vitro antifungal activity against Trichophyton mentagrophytes
|
Arthroderma benhamiae
|
1.0
%
|
|
|
In vitro antifungal activity against Trichophyton rubrum
|
Trichophyton rubrum
|
1.0
%
|
|
|
Percent Inhibition of growth of uM
|
Trypanosoma cruzi
|
18.0
%
|
|
|
Inhibition of lanosterol 14-alpha-demethylase in hamster hepatic microsomes
|
None
|
24.5
nM
|
|
|
Inhibition of lanosterol 14-alpha-demethylase in hamster hepatic microsomes
|
None
|
63.5
nM
|
|
|
Inhibition of lanosterol 14-alpha-demethylase of rat hepatic microsomes
|
Rattus norvegicus
|
65.0
nM
|
|
|
In vitro inhibitory concentration against human CYP11B2 expressed in V79MZh hamster fibroblasts incubated with 100 nM of substrate deoxy-corticosterone in presence of the compound
|
Homo sapiens
|
81.0
nM
|
|
|
In vitro inhibitory concentration against human CYP11B1 expressed in V79 MZh hamster fibroblasts incubated with 100 nM of substrate deoxy-corticosterone in presence of the compound
|
Homo sapiens
|
224.0
nM
|
|
|
In vitro inhibition against bovine cytochrome P450 11B with 200 uM corticosterone
|
CYP11B
|
78.0
%
|
|
|
In vitro inhibition against human placental cytochrome P450 17 expressed in Escherichia coli with 2.5 uM progesterone
|
Homo sapiens
|
40.0
%
|
|
|
In vitro inhibition of human CYP17 expressed in Escherichia coli incubated with 2.5 uM of substrate progesterone in presence of 2.5 uM of compound
|
Homo sapiens
|
40.0
%
|
|
|
In vitro inhibition of human CYP11B2 expressed in Schizosaccharomyces pombe incubated with 100 nM of substrate deoxy-corticosterone in presence of 500 nM of compound
|
Homo sapiens
|
36.0
%
|
|
|
Inhibitory concentration against human hepatic cytochrome P450 3A4 enzyme
|
Homo sapiens
|
50.0
nM
|
|
|
Inhibitory concentration against human cytochrome P450 11B1 expressed in fission yeast, incubated with [14C]deoxycorticosterone
|
Homo sapiens
|
224.0
nM
|
|
|
Inhibitory concentration against human cytochrome P450 11B2 expressed in fission yeast, incubated with [14C]deoxycorticosterone
|
Homo sapiens
|
81.0
nM
|
|
|
Percent inhibition against recombinant human cytochrome P450 17A1 using progesterone
|
Homo sapiens
|
40.0
%
|
|
|
Percent inhibition against human cytochrome P450 11B2 expressed in fission yeast, incubated with [14C]deoxycorticosterone
|
Homo sapiens
|
36.0
%
|
|
|
Inhibition of human CYP11B2 expressed in Schizosaccharomyces pombe at 500 nM
|
Homo sapiens
|
36.0
%
|
|
|
Inhibition of human CYP11B1 expressed in V79 11B1 cells
|
Homo sapiens
|
224.0
nM
|
|
|
Inhibition of human CYP11B2 expressed in V79 11B2 cells
|
Homo sapiens
|
81.0
nM
|
|
|
Inhibition of human placental CYP19
|
Homo sapiens
|
40.0
nM
|
|
|
Inhibition of human CYP3A4
|
Homo sapiens
|
50.0
nM
|
|
|
Inhibition of rat testis 17,20 lyase component of P450-17alpha at 10 uM
|
Rattus norvegicus
|
78.69
%
|
|
|
Inhibition of rat testis 17-alpha-hydroxylase component of P450-17alpha at 10 uM
|
Rattus norvegicus
|
61.54
%
|
|
|
Inhibition of human recombinant aromatase
|
Homo sapiens
|
900.0
nM
|
|
|
Inhibition of human CYP24 hydroxylase expressed in V79 cells
|
Homo sapiens
|
312.0
nM
|
|
|
Inhibition of human recombinant aromatase at 300 nM after 30 mins relative to control
|
Homo sapiens
|
81.7
%
|
|
|
Inhibition of human recombinant aromatase at 1 uM after 30 mins relative to control
|
Homo sapiens
|
84.2
%
|
|
|
Inhibition of human recombinant aromatase at 3 uM after 30 mins relative to control
|
Homo sapiens
|
87.5
%
|
|
|
Inhibition of human recombinant aromatase at 10 uM after 30 mins relative to control
|
Homo sapiens
|
87.9
%
|
|
|
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation
|
Homo sapiens
|
210.0
nM
|
|
|
Inhibition of hepatic CYP1A2 at 1 uM
|
None
|
8.0
%
|
|
|
Inhibition of hepatic CYP1A2 at 10 uM
|
None
|
38.0
%
|
|
|
Inhibition of hepatic CYP2C9 at 1 uM
|
None
|
21.0
%
|
|
|
Inhibition of hepatic CYP2C9 at 10 uM
|
None
|
75.0
%
|
|
|
Inhibition of hepatic CYP2C19 at 1 uM
|
None
|
24.0
%
|
|
|
Inhibition of hepatic CYP2C19 at 10 uM
|
None
|
1.0
%
|
|
|
Inhibition of hepatic CYP3A4 at 1 uM
|
None
|
1.0
%
|
|
|
Inhibition of hepatic CYP3A4 at 10 uM
|
None
|
4.0
%
|
|
|
Inhibition of human CYP17 expressed in Escherichia coli co-expressed with NADPH-P450 reductase at 1 uM
|
Homo sapiens
|
19.0
%
|
|
|
Inhibition of recombinant CYP3A4 at 1 uM
|
None
|
96.0
%
|
|
|
Inhibition of recombinant CYP3A4 at 10 uM
|
None
|
98.0
%
|
|
|
Inhibition of recombinant CYP1A2 at 1 uM
|
None
|
8.0
%
|
|
|
Inhibition of recombinant CYP1A2 at 10 uM
|
None
|
38.0
%
|
|
|
Inhibition of recombinant CYP2C9 at 1 uM
|
None
|
21.0
%
|
|
|
Inhibition of recombinant CYP2C9 at 10 uM
|
None
|
75.0
%
|
|
|
Inhibition of recombinant CYP2C19 at 1 uM
|
None
|
24.0
%
|
|
|
Inhibition of recombinant CYP2C19 at 10 uM
|
None
|
79.0
%
|
|
|
Inhibition of recombinant CYP2B6 at 1 uM
|
None
|
11.0
%
|
|
|
Inhibition of recombinant CYP2B6 at 10 uM
|
None
|
57.0
%
|
|
|
Inhibition of recombinant CYP2D6 at 1 uM
|
None
|
1.0
%
|
|
|
Inhibition of recombinant CYP2D6 at 10 uM
|
None
|
4.0
%
|
|
|
Inhibition of human CYP3A4
|
Homo sapiens
|
54.0
nM
|
|
|
Binding affinity to human His-tagged CYP51 expressed in Escherichia coli
|
Homo sapiens
|
110.0
nM
|
|
|
Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay
|
Homo sapiens
|
190.0
nM
|
|
|
Displacement of [131I]IMTO from CYP450c 11 in Wistar rat adrenal membrane
|
Rattus norvegicus
|
0.71
nM
|
|
|
Inhibition of refampicin-mediated PXR activation in HepG2 cells
|
None
|
93.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsome
|
Homo sapiens
|
103.0
%
|
|
Inhibition of CYP3A4 in human liver microsome
|
Homo sapiens
|
20.0
nM
|
|
|
Inhibition of human recombinant CYP3A4 expressed in insect microsomes
|
Homo sapiens
|
57.0
nM
|
|
|
Inhibition of human recombinant CYP17 expressed in Escherichia coli coexpressing NADPH-P450 reductase
|
Homo sapiens
|
72.0
nM
|
|
|
Inhibition of human CYP11B1 expressed in hamster V79MZh11B1 cells
|
Homo sapiens
|
127.0
nM
|
|
|
Inhibition of human CYP11B2 expressed in hamster V79MZh11B2 cells
|
Homo sapiens
|
67.0
nM
|
|
|
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes
|
None
|
72.0
nM
|
|
|
Inhibition of hepatic CYP3A4 expressed in insect microsomes at 1 uM
|
None
|
96.0
%
|
|
|
Inhibition of hepatic CYP1A2 expressed in insect microsomes at 1 uM
|
None
|
8.0
%
|
|
|
Inhibition of hepatic CYP2B6 expressed in insect microsomes at 1 uM
|
None
|
11.0
%
|
|
|
Inhibition of hepatic CYP2D6 expressed in insect microsomes at 1 uM
|
None
|
1.0
%
|
|
|
Antimicrobial activity against Candida albicans ATCC 10231 at 6.25 ug/ml after 24 hrs
|
Candida albicans
|
100.0
%
|
|
|
Antimicrobial activity against Candida albicans C126 isolate at 6.25 ug/ml after 24 hrs
|
Candida albicans
|
100.0
%
|
|
|
Antimicrobial activity against Candida albicans C127 isolate at 6.25 ug/ml after 24 hrs
|
Candida albicans
|
100.0
%
|
|
|
Antimicrobial activity against Candida albicans C128 isolate at 6.25 ug/ml after 24 hrs
|
Candida albicans
|
100.0
%
|
|
|
Antimicrobial activity against Cryptococcus neoformans IM 972724 isolate at 6.25 ug/ml after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antimicrobial activity against Candida albicans C129 isolate at 6.25 ug/ml after 24 hrs
|
Candida albicans
|
100.0
%
|
|
|
Antimicrobial activity against Candida albicans C130 isolate at 6.25 ug/ml after 24 hrs
|
Candida albicans
|
100.0
%
|
|
|
Antimicrobial activity against Candida glabrata C115 isolate at 6.25 ug/ml after 24 hrs
|
Candida glabrata
|
100.0
%
|
|
|
Antimicrobial activity against Candida tropicalis C131 isolate at 6.25 ug/ml after 24 hrs
|
Candida tropicalis
|
100.0
%
|
|
|
Antimicrobial activity against Candida parapsilosis C124 isolate at 6.25 ug/ml after 24 hrs
|
Candida parapsilosis
|
100.0
%
|
|
|
Antimicrobial activity against Candida krusei C117 isolate at 6.25 ug/ml after 24 hrs
|
Pichia kudriavzevii
|
100.0
%
|
|
|
Antimicrobial activity against Cryptococcus neoformans ATCC 32264 at 6.25 ug/ml after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antimicrobial activity against Cryptococcus neoformans IM 983040 isolate at 6.25 ug/ml after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antimicrobial activity against Cryptococcus neoformans IM 042074 isolate at 6.25 ug/ml after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antimicrobial activity against Cryptococcus neoformans IM 983036 isolate at 6.25 ug/ml after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antimicrobial activity against Cryptococcus neoformans IM 00319 isolate at 6.25 ug/ml after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antimicrobial activity against Cryptococcus neoformans IM 972751 isolate at 6.25 ug/ml after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antimicrobial activity against Cryptococcus neoformans IM 031631 isolate at 6.25 ug/ml after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antimicrobial activity against Cryptococcus neoformans IM 031706 isolate at 6.25 ug/ml after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antimicrobial activity against Cryptococcus neoformans IM 961951 isolate at 6.25 ug/ml after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antimicrobial activity against Cryptococcus neoformans IM 052470 isolate at 6.25 ug/ml after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes
|
Homo sapiens
|
57.0
nM
|
|
|
Antimicrobial activity against Candida albicans by broth microdilution method
|
Candida albicans
|
0.001
ug.mL-1
|
|
|
Antimicrobial activity against Cryptococcus neoformans by broth microdilution method
|
Cryptococcus neoformans
|
0.001
ug.mL-1
|
|
|
Antimicrobial activity against Sporothrix schenckii by broth microdilution method
|
Sporothrix schenckii
|
0.026
ug.mL-1
|
|
|
Antimicrobial activity against Trichophyton mentagrophytes by broth microdilution method
|
Trichophyton mentagrophytes
|
2.12
ug.mL-1
|
|
|
Antimicrobial activity against Aspergillus fumigatus by broth microdilution method
|
Aspergillus fumigatus
|
0.008
ug.mL-1
|
|
|
Antimicrobial activity against Candida parapsilosis ATCC 22019 by broth microdilution method
|
Candida parapsilosis
|
0.024
ug.mL-1
|
|
|
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation
|
Homo sapiens
|
720.0
nM
|
|
|
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy
|
Homo sapiens
|
82.3
%
|
|
|
Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigotes expressing beta-galactosidase in mouse 3T3 fibroblast after 7 days by alamar blue assay
|
Trypanosoma cruzi
|
0.3
nM
|
|
|
Inhibition of human recombinant CYP3A4
|
Homo sapiens
|
40.0
nM
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as growth inhibition at 100 uM after 24 hrs
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as growth inhibition at 50 uM after 24 hrs
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as growth inhibition at 25 uM after 24 hrs
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as growth inhibition at 12.5 uM after 24 hrs
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as growth inhibition at 200 uM after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as growth inhibition at 100 uM after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as growth inhibition at 50 uM after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as growth inhibition at 25 uM after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as growth inhibition at 12.5 uM after 48 hrs
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as growth inhibition at 200 uM after 24 hrs
|
Candida albicans
|
100.0
%
|
|
|
Cytotoxicity against mouse M109 cells
|
Mus musculus
|
17.0
ug.mL-1
|
|
|
Inhibition of human CYP3A4 by radiometric assay
|
Homo sapiens
|
245.0
nM
|
|
|
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline
|
Homo sapiens
|
24.0
nM
|
|
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline
|
Homo sapiens
|
25.12
nM
|
|
|
Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of encystment at 5 ug/mL after 7 days
|
Balamuthia mandrillaris
|
0.0
%
|
|
|
Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of encystment at 10 ug/mL after 7 days
|
Balamuthia mandrillaris
|
0.0
%
|
|
|
Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of amoeba-induced cytopathogenicity at 5 ug/mL after 24 hrs by LDH release assay
|
Balamuthia mandrillaris
|
14.0
%
|
|
|
Antimicrobial activity against Balamuthia mandrillaris ATCC 50209 infected in HBMEC assessed as inhibition of amoeba-induced cytopathogenicity at 10 ug/mL after 24 hrs by LDH release assay
|
Balamuthia mandrillaris
|
88.5
%
|
|
|
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome
|
None
|
72.0
nM
|
|
|
Inhibition of recombinant CYP11B1 expressed in V79MZh11B1 cells at 0.2 uM
|
None
|
61.0
%
|
|
|
Inhibition of recombinant CYP11B1 expressed in expressed in V79MZh11B1 cells at 2 uM
|
None
|
93.0
%
|
|
|
Inhibition of P-gp in human Caco-2 cells assessed as increase in influx permeability from apical to basolateral side at 50 uM after 120 mins
|
Homo sapiens
|
45.0
%
|
|
|
Inhibition of P-gp in human Caco-2 cells assessed as decrease in efflux permeability from basolateral to apical side at 50 uM after 120 mins
|
Homo sapiens
|
45.0
%
|
|
|
Inhibition of CYP3A4
|
None
|
199.99
nM
|
|
|
Inhibition of human recombinant aromatase
|
Homo sapiens
|
800.0
nM
|
|
|
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis
|
Homo sapiens
|
30.0
nM
|
|
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis
|
Homo sapiens
|
33.11
nM
|
|
|
Inhibition of human CYP3A4
|
Homo sapiens
|
4.0
nM
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 200 uM after 48 hrs by microbroth dilution method
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 100 uM after 48 hrs by microbroth dilution method
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 50 uM after 48 hrs by microbroth dilution method
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 25 uM after 48 hrs by microbroth dilution method
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 12.5 uM after 48 hrs by microbroth dilution method
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 6.25 uM after 48 hrs by microbroth dilution method
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 3.125 uM after 48 hrs by microbroth dilution method
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of fungal growth at 200 uM after 24 hrs by microbroth dilution method
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of fungal growth at 100 uM after 24 hrs by microbroth dilution method
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of fungal growth at 50 uM after 24 hrs by microbroth dilution method
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of fungal growth at 25 uM after 24 hrs by microbroth dilution method
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of fungal growth at 12.5 uM after 24 hrs by microbroth dilution method
|
Candida albicans
|
100.0
%
|
|
|
Inhibition of human recombinant aromatase at 1 uM
|
Homo sapiens
|
84.2
%
|
|
|
Inhibition of human recombinant aromatase at 10 uM
|
Homo sapiens
|
92.5
%
|
|
|
Inhibition of human recombinant aromatase at 3 uM
|
Homo sapiens
|
83.8
%
|
|
|
Inhibition of human recombinant aromatase at 0.3 uM
|
Homo sapiens
|
89.3
%
|
|
|
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay
|
Homo sapiens
|
30.0
nM
|
|
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay
|
Homo sapiens
|
33.11
nM
|
|
|
Inhibition of human placental microsome CYP19
|
Homo sapiens
|
60.0
nM
|
|
|
Inhibition of human recombinant CYP3A4
|
Homo sapiens
|
11.0
nM
|
|
|
Inhibition of aromatase from human placental microsomes at 10 uM
|
Homo sapiens
|
17.7
%
|
|
|
Inhibition of human CYP11B1 expressed in hamster V79MZh cells
|
Homo sapiens
|
127.0
nM
|
|
|
Inhibition of human CYP11B2 expressed in hamster V79MZh cells
|
Homo sapiens
|
67.0
nM
|
|
|
Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes
|
None
|
57.0
nM
|
|
|
Inhibition of CYP24A1 in human epidermal keratinocytes
|
Homo sapiens
|
126.0
nM
|
|
|
Inhibition of human CYP24A1 expressed in chinese hamster V79 cells
|
Homo sapiens
|
312.0
nM
|
|
|
Inhibition of human recombinant CYP24A1 expressed in chinese hamster V79 cells using [3H-1-beta]calcitriol after 60 mins by scintillation counting
|
Homo sapiens
|
520.0
nM
|
|
|
Inhibition of 17,20-lyase activity of rat testicular microsomal P450-17alpha
|
Rattus norvegicus
|
206.0
nM
|
|
|
Inhibition of CYP24A1 expressed in CHO cells
|
None
|
520.0
nM
|
|
|
Antifungal activity against Trichophyton rubrum ATCC 10218 by CLSI method
|
Trichophyton rubrum
|
20.0
nM
|
|
|
Antifungal activity against Trichophyton rubrum ATCC MYA-4438 by CLSI method
|
Trichophyton rubrum
|
10.0
nM
|
|
|
Antifungal activity against Trichophyton mentagrophytes ATCC 9533 by CLSI method
|
Trichophyton mentagrophytes
|
200.0
nM
|
|
|
Antifungal activity against Trichophyton mentagrophytes ATCC MYA-4439 by CLSI method
|
Trichophyton mentagrophytes
|
100.0
nM
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 66031 after 72 hrs by CLSI method
|
Cryptococcus neoformans
|
20.0
nM
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 90113 after 72 hrs by CLSI method
|
Cryptococcus neoformans
|
100.0
nM
|
|
|
Antifungal activity against Candida tropicalis ATCC 750 after 48 hrs by CLSI method
|
Candida tropicalis
|
40.0
nM
|
|
|
Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by CLSI method
|
Candida parapsilosis
|
40.0
nM
|
|
|
Antifungal activity against Candida krusei ATCC 6258 after 48 hrs by CLSI method
|
Pichia kudriavzevii
|
400.0
nM
|
|
|
Antifungal activity against Candida glabrata ATCC 90030 after 48 hrs by CLSI methodCandida glabrata
|
Candida glabrata
|
700.0
nM
|
|
|
Antifungal activity against Fluconazole resistant Candida albicans clinical isolate 17 after 48 hrs by CLSI method
|
Candida albicans
|
300.0
nM
|
|
|
Antifungal activity against Fluconazole resistant Candida albicans clinical isolate 1 after 48 hrs by CLSI method
|
Candida albicans
|
10.0
nM
|
|
|
Antifungal activity against Candida albicans ATCC 200955 after 48 hrs by CLSI method
|
Candida albicans
|
10.0
nM
|
|
|
Antifungal activity against Candida albicans ATCC 90028 after 48 hrs by CLSI method
|
Candida albicans
|
10.0
nM
|
|
|
Antifungal activity against Candida albicans ATCC 32354 after 48 hrs by CLSI method
|
Candida albicans
|
10.0
nM
|
|
|
Antifungal activity against Candida albicans ATCC 14053 after 48 hrs by CLSI method
|
Candida albicans
|
10.0
nM
|
|
|
Antifungal activity against Candida albicans ATCC 60193 after 48 hrs by CLSI method
|
Candida albicans
|
10.0
nM
|
|
|
Inhibition of human CYP11B1 expressed in hamster V79MZ cells using 11-deoxycorticosterone substrate
|
Homo sapiens
|
127.0
nM
|
|
|
Inhibition of human CYP11B2 expressed in hamster V79MZ cells using 11-deoxycorticosterone substrate
|
Homo sapiens
|
67.0
nM
|
|
|
Inhibition of human CYP3A4
|
Homo sapiens
|
50.0
nM
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of fungal growth at 200 uM after 24 hrs by microplate analysis
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of fungal growth at 100 uM after 24 hrs by microplate analysis
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of fungal growth at 50 uM after 24 hrs by microplate analysis
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of fungal growth at 25 uM after 24 hrs by microplate analysis
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of fungal growth at 12.5 uM after 24 hrs by microplate analysis
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Candida albicans ATCC 10231 assessed as inhibition of fungal growth at 6.25 uM after 24 hrs by microplate analysis
|
Candida albicans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 200 uM after 48 hrs by microplate analysis
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 100 uM after 48 hrs by microplate analysis
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 50 uM after 48 hrs by microplate analysis
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 25 uM after 48 hrs by microplate analysis
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 12.5 uM after 48 hrs by microplate analysis
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Antifungal activity against Cryptococcus neoformans ATCC 32264 assessed as inhibition of fungal growth at 6.25 uM after 48 hrs by microplate analysis
|
Cryptococcus neoformans
|
100.0
%
|
|
|
Inhibition of CYP3A4 after 30 mins by fluorometric assay
|
None
|
7.8
nM
|
|
|
Binding affinity to human CYP51
|
Homo sapiens
|
110.0
nM
|
|
|
Binding affinity to bovine CYP51
|
Bos taurus
|
320.0
nM
|
|
|
Inhibition of human CYP3A4 expressed in baculovirus-infected insect microsomes
|
Homo sapiens
|
57.0
nM
|
|
|
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)
|
None
|
531.0
nM
|
|
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)
|
None
|
282.0
nM
|
|
|
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)
|
None
|
16.0
nM
|
|
|
Inhibition of human recombinant aromatase assessed as conversion of O-dibenzylfluorescein benzyl ester substrate to fluorescein byproduct by fluorometric assay
|
Homo sapiens
|
400.0
nM
|
|
Inhibition of human recombinant aromatase assessed as conversion of O-dibenzylfluorescein benzyl ester substrate to fluorescein byproduct by fluorometric assay
|
Homo sapiens
|
398.11
nM
|
|
|
Inhibition of human CYP11B1 expressed in hamster V79 MZ cells using [3H] 11 deoxycorticosterone as substrate by HPLC radioflow detector
|
Homo sapiens
|
127.0
nM
|
|
|
Inhibition of human CYP11B2 expressed in hamster V79 MZ cells using [3H] 11 deoxycorticosterone as substrate by HPLC radioflow detector
|
Homo sapiens
|
67.0
nM
|
|
|
Inhibition of human CYP3A4 in liver microsomes
|
Homo sapiens
|
70.0
nM
|
|
|
Inhibition of CYP3A4 at 10 uM
|
None
|
93.0
%
|
|
|
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting
|
Homo sapiens
|
53.6
%
|
|
|
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting
|
Homo sapiens
|
24.7
%
|
|
|
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting
|
Homo sapiens
|
44.0
%
|
|
|
Inhibition of human CYP3A4 at 10 uM
|
Homo sapiens
|
93.0
%
|
|
|
Inhibition of CYP3A4/5 in human intestinal microsomes using midazolam as substrate after 4 mins
|
Homo sapiens
|
81.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation to 1'-hydroxymidazolam at 1 uM after 10 mins relative to control
|
Homo sapiens
|
95.0
%
|
|
|
Inhibition of CYP2D6 in human liver microsomes assessed as bufuralol hydroxylation to 4'-hydroxybufuralol at 1 uM after 10 mins relative to control
|
Homo sapiens
|
4.0
%
|
|
|
Inhibition of CYP1A2 in human liver microsomes assessed as phenacetin demethylation to acetaminophen at 1 uM after 10 mins relative to control
|
Homo sapiens
|
22.0
%
|
|
|
Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control
|
Homo sapiens
|
22.0
%
|
|
|
Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi infected in mouse NIH/3T3 cells after 48 hrs by Hoechst staining assay
|
Trypanosoma cruzi
|
22.7
nM
|
|
|
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
98.1
%
|
|
|
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
69.11
%
|
|
|
Inhibition of Wistar rat testicular C17,20-lyase using [3H]17-hydroxyprogesterone as substrate preincubated for 20 mins
|
Rattus norvegicus
|
320.0
nM
|
|
|
Inhibition of CYP3A4 (unknown origin) by fluorescence assay
|
Homo sapiens
|
24.0
nM
|
|
|
Inhibition of CYP3A4 (unknown origin) at 10 uM relative to control
|
Homo sapiens
|
95.34
%
|
|
|
Inhibition of recombinant CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate
|
Homo sapiens
|
280.0
nM
|
|
|
Inhibition of N-terminally MBP-fused human CYP24A1 by cell-free assay
|
Homo sapiens
|
470.0
nM
|
|
Inhibition of N-terminally MBP-fused human CYP24A1 by cell-free assay
|
Homo sapiens
|
35.0
nM
|
|
|
Inhibition of mouse CYP27B1 by cell-free assay
|
Mus musculus
|
360.0
nM
|
|
Inhibition of mouse CYP27B1 by cell-free assay
|
Mus musculus
|
58.0
nM
|
|
|
Inhibition of human CYP3A4 at 10 uM
|
Homo sapiens
|
99.0
%
|
|
|
Inhibition of CYP3A4 (unknown origin) using AMMC by fluorescence assay
|
Homo sapiens
|
25.0
nM
|
|
|
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins at 0.1 uM by fluorescence assay
|
Homo sapiens
|
33.9
%
|
|
|
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins at 1 uM by fluorescence assay
|
Homo sapiens
|
87.2
%
|
|
|
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins at 10 uM by fluorescence assay
|
Homo sapiens
|
92.3
%
|
|
|
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins by fluorescence assay
|
Homo sapiens
|
200.0
nM
|
|
|
Inhibition of human recombinant MDR1 in cell membrane fraction preincubated for 5 mins at 0.01 uM measured after 40 mins by Pgp-Glo luciferase assay
|
Homo sapiens
|
15.0
%
|
|
|
Inhibition of human recombinant MDR1 in cell membrane fraction preincubated for 5 mins at 0.1 uM measured after 40 mins by Pgp-Glo luciferase assay
|
Homo sapiens
|
15.0
%
|
|
|
Inhibition of human recombinant MDR1 in cell membrane fraction preincubated for 5 mins at 1 uM measured after 40 mins by Pgp-Glo luciferase assay
|
Homo sapiens
|
29.4
%
|
|
|
Inhibition of human recombinant MDR1 in cell membrane fraction preincubated for 5 mins at 10 uM measured after 40 mins by Pgp-Glo luciferase assay
|
Homo sapiens
|
46.4
%
|
|
|
Inhibition of human recombinant MDR1 in cell membrane fraction preincubated for 5 mins at 100 uM measured after 40 mins by Pgp-Glo luciferase assay
|
Homo sapiens
|
74.2
%
|
|
|
Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC
|
Homo sapiens
|
59.8
%
|
|
|
Inhibition of recombinant human CYP3A4 preincubated at 10 uM for 5 mins before fluorescent substrate addition by fluorescence assay
|
Homo sapiens
|
14.4
%
|
|
|
Inhibition of human aldosterone synthase expressed in V79 MZ cells
|
Homo sapiens
|
650.0
nM
|
|
|
Inhibition of CYP3A4 in human liver microsome
|
Homo sapiens
|
62.0
nM
|
|
|
Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method
|
Homo sapiens
|
470.0
nM
|
|
Inhibition of human MBP-tagged CYP24A1 expressed in Escherichia coli using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method
|
Homo sapiens
|
33.0
nM
|
|
|
Inhibition of mouse CYP27B1 using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method
|
Mus musculus
|
360.0
nM
|
|
Inhibition of mouse CYP27B1 using 1,25(OH)2D3 substrate in presence of bovine adrenodoxin, adrenodoxin reductase and NADPH incubated at 37 degC for 25 mins by HPLC method
|
Mus musculus
|
58.0
nM
|
|
|
DNDI: Chagas in Vitro, 96 hour
|
Trypanosoma cruzi
|
270.0
nM
|
|
|
Inhibition of human recombinant CYP3A4 assessed as effect on conversion of beetle D-luciferin derivative into D-luciferin by firefly luciferase based luminescence assay
|
Homo sapiens
|
140.0
nM
|
|
|
Inhibition of human CYP17 using 17alpha-hydroxypregnenolone substrate relative to control
|
Homo sapiens
|
67.0
%
|
|
|
Inhibition of human CYP17 using 17alpha-hydroxypregnenolone substrate
|
Homo sapiens
|
78.0
nM
|
|
Inhibition of human CYP17 using 17alpha-hydroxypregnenolone substrate
|
Homo sapiens
|
38.0
nM
|
|
|
Antifungal activity against Aspergillus niger assessed as growth inhibition at 0.5 mg/ml after 48 hrs by well diffusion method
|
Aspergillus niger
|
22.67
ug.mL-1
|
|
|
Antifungal activity against Aspergillus fumigatus assessed as growth inhibition at 0.5 mg/ml after 48 hrs by well diffusion method
|
Aspergillus fumigatus
|
20.67
ug.mL-1
|
|
|
Antifungal activity against Aspergillus terreus assessed as growth inhibition at 0.5 mg/ml after 48 hrs by well diffusion method
|
Aspergillus terreus
|
20.0
ug.mL-1
|
|
|
Inhibition of human CYP4F2 in human liver microsomes assessed as fingolimod metabolism
|
Homo sapiens
|
740.0
nM
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis
|
Homo sapiens
|
100.0
nM
|
|
|
Inhibition of CYP3A4 activity in human liver microsomes assessed as dibenzo fluuorescene oxidation up to 40 uM
|
Homo sapiens
|
9.8
nM
|
|
|
Inhibition of CYP3A4 activity in human liver microsomes using midazolam as a substrate by LC/MS analysis
|
Homo sapiens
|
7.0
nM
|
|
|
Inhibition of CYP3A4 activity in human liver microsomes using nifedipine as a substrate by LC/MS analysis
|
Homo sapiens
|
11.0
nM
|
|
|
Inhibition of CYP3A4 activity in human liver microsomes using testosterone as a substrate by LC/MS analysis
|
Homo sapiens
|
49.0
nM
|
|
|
Inhibition of human recombinant CYP3A4 assessed as remaining enzyme activity by measuring conversion of luciferin-PPXE into D-luciferin by luminescence CYP3A4 P450-Glo assay relative to untreated control
|
Homo sapiens
|
140.0
nM
|
|
|
Inhibition of human CYP3A4 at 10 uM preincubated for 10 mins with cofactor followed by mixture of enzyme-substrate addition by fluorescence assay relative to control
|
Homo sapiens
|
95.2
%
|
|
|
Inhibition of CYP3A4 (unknown origin) at 20 uM by luminescent readout-based method
|
Homo sapiens
|
95.37
%
|
|
|
Inhibition of CYP3A4 (unknown origin)
|
Homo sapiens
|
180.0
nM
|
|
|
Inhibition of human recombinant CYP3A4 assessed as conversion of luciferin-PPXE to D-luciferin by luminescence Glo assay
|
Homo sapiens
|
140.0
nM
|
|
|
Inhibition of CYP3A4 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition
|
Homo sapiens
|
60.0
nM
|
|
|
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.
|
Homo sapiens
|
400.0
nM
|
|
|
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.
|
Homo sapiens
|
150.0
nM
|
|
|
Inhibition of recombinant human CYP3A4 by luminescence -based microplate reader assay
|
Homo sapiens
|
140.0
nM
|
|
|
Inhibition of CYP3A4 (unknown origin) at 20 uM by P450-glo assay
|
Homo sapiens
|
95.37
%
|
|
|
Inhibition of human recombinant CYP3A4 using BFC as substrate incubated for 30 mins by fluorimetry
|
Homo sapiens
|
280.0
nM
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis
|
Homo sapiens
|
4.0
nM
|
|
|
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis
|
Homo sapiens
|
1.0
nM
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate at 10 uM preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis relative to control
|
Homo sapiens
|
100.0
%
|
|
|
Inhibition of recombinant human CYP3A4 by P450-Glo luminescence assay
|
Homo sapiens
|
240.0
nM
|
|
|
Inhibition of Wistar rat testicular C17,20-lyase assessed as androst-4-ene-3,17-dione formation using [3H]17-hydroxyprogesterone as substrate in presence of NADPH
|
Rattus norvegicus
|
320.0
nM
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation at 0.005 uM by LC/MS/MS analysis
|
Homo sapiens
|
34.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation at 0.01 uM by LC/MS/MS analysis
|
Homo sapiens
|
53.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation at 0.02 uM by LC/MS/MS analysis
|
Homo sapiens
|
70.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation at 0.04 uM by LC/MS/MS analysis
|
Homo sapiens
|
82.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation at 0.08 uM by LC/MS/MS analysis
|
Homo sapiens
|
90.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation at 0.16 uM by LC/MS/MS analysis
|
Homo sapiens
|
94.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 4-OH-midazolam formation at 0.005 uM by LC/MS/MS analysis
|
Homo sapiens
|
37.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 4-OH-midazolam formation at 0.01 uM by LC/MS/MS analysis
|
Homo sapiens
|
57.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 4-OH-midazolam formation at 0.02 uM by LC/MS/MS analysis
|
Homo sapiens
|
74.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 4-OH-midazolam formation at 0.04 uM by LC/MS/MS analysis
|
Homo sapiens
|
85.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 4-OH-midazolam formation at 0.08 uM by LC/MS/MS analysis
|
Homo sapiens
|
92.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 4-OH-midazolam formation at 0.16 uM by LC/MS/MS analysis
|
Homo sapiens
|
95.0
%
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation by LC/MS/MS analysis
|
Homo sapiens
|
9.1
nM
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 4-OH-midazolam formation by LC/MS/MS analysis
|
Homo sapiens
|
7.4
nM
|
|
|
Inhibition of CYP3A4 in pooled human hepatic microsomes using testosterone substrate in presence of NADPH
|
Homo sapiens
|
28.5
nM
|
|
|
Inhibition of recombinant CYP17 (unknown origin) overexpressed in human AD293 cells using [21-3H]17alpha-hydroxyl-pregenolone as substrate preincubated for 60 mins followed by substrate addition measured after 4 hrs by Topcount method
|
Homo sapiens
|
48.0
nM
|
|
Inhibition of recombinant CYP17 (unknown origin) overexpressed in human AD293 cells using [21-3H]17alpha-hydroxyl-pregenolone as substrate preincubated for 60 mins followed by substrate addition measured after 4 hrs by Topcount method
|
Homo sapiens
|
93.0
nM
|
|
|
Inhibition of recombinant CYP11B1 (unknown origin) overexpressed in human AD293 cells assessed as reduction in cortisol formation preincubated for 60 mins followed by addition of 11-deoxycortisol as substrate measured after 12 hrs by LC-MS/MS analysis
|
Homo sapiens
|
116.0
nM
|
|
|
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis
|
Homo sapiens
|
146.0
nM
|
|
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis
|
Homo sapiens
|
133.0
nM
|
|
|
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in nifedipine oxidation incubated for 10 mins
|
Homo sapiens
|
31.7
nM
|
|
|
Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM.
|
Homo sapiens
|
400.0
nM
|
|
|
Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM.
|
Homo sapiens
|
150.0
nM
|
|
|
Fluorescent High Throughput P450 Assay: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5). Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. Concentration-response curves performed in duplicate for known inhibitors for each isoenzyme were tested in ever
|
Homo sapiens
|
12.0
nM
|
|
|
Fluorescent High Throughput P450 Assay: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5). Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. Concentration-response curves performed in duplicate for known inhibitors for each isoenzyme were tested in ever
|
None
|
120.0
nM
|
|
|
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.
|
Homo sapiens
|
500.0
nM
|
|
|
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.
|
Homo sapiens
|
500.0
nM
|
|
|
Fluorescent High Throughput P450 Assays: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5).Materials and Methods: Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths.
|
Homo sapiens
|
12.0
nM
|
|
|
Fluorescent High Throughput P450 Assays: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5).Materials and Methods: Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths.
|
None
|
120.0
nM
|
|
|
Inhibition Assay: V79 MZh11B1 and V79 MZh 11B2 cells (8˙10^5 cells per well) were grown to confluency on 24-well cell culture plates with 1.9 cm^2 culture area per well (Nunc, Roskilde, Denmark). Before the test, the DMEM culture medium present was removed, and 450 μl of fresh DMEM with inhibitor was added for at least three concentrations to each well to determine the IC50. After preincubation (60 min, 37 °C.), the reaction was started by adding 50 μl of DMEM with 2.5 μl of solution of the substrate 11-deoxycorticosterone (20 μM, containing 1.25 nCi of [4-14C]11-deoxycorticosterone in ethanol). Thereafter, the plate was stored at 37 °C. and 5% CO2 in a CO2 incubator. The V79 MZh 11B1 cells were incubated for 120 min, and the V79 MZh 11B2 cells were incubated for 40 min. Controls without inhibitor were treated in the same way. The enzyme reactions were quenched by extracting the supernatant with 500 μl of EtOAc. The samples were centrifuged (10,000 g, 2 min), the solvent was removed and evaporated. The residue was taken up in 10 μl of chloroform and analyzed by HPTLC (see below).
|
Homo sapiens
|
224.0
nM
|
|
Inhibition Assay: V79 MZh11B1 and V79 MZh 11B2 cells (8˙10^5 cells per well) were grown to confluency on 24-well cell culture plates with 1.9 cm^2 culture area per well (Nunc, Roskilde, Denmark). Before the test, the DMEM culture medium present was removed, and 450 μl of fresh DMEM with inhibitor was added for at least three concentrations to each well to determine the IC50. After preincubation (60 min, 37 °C.), the reaction was started by adding 50 μl of DMEM with 2.5 μl of solution of the substrate 11-deoxycorticosterone (20 μM, containing 1.25 nCi of [4-14C]11-deoxycorticosterone in ethanol). Thereafter, the plate was stored at 37 °C. and 5% CO2 in a CO2 incubator. The V79 MZh 11B1 cells were incubated for 120 min, and the V79 MZh 11B2 cells were incubated for 40 min. Controls without inhibitor were treated in the same way. The enzyme reactions were quenched by extracting the supernatant with 500 μl of EtOAc. The samples were centrifuged (10,000 g, 2 min), the solvent was removed and evaporated. The residue was taken up in 10 μl of chloroform and analyzed by HPTLC (see below).
|
Homo sapiens
|
224.0
nM
|
|
|
Inhibition Assay: V79 MZh11B1 and V79 MZh 11B2 cells (8˙10^5 cells per well) were grown to confluency on 24-well cell culture plates with 1.9 cm^2 culture area per well (Nunc, Roskilde, Denmark). Before the test, the DMEM culture medium present was removed, and 450 μl of fresh DMEM with inhibitor was added for at least three concentrations to each well to determine the IC50. After preincubation (60 min, 37 °C.), the reaction was started by adding 50 μl of DMEM with 2.5 μl of solution of the substrate 11-deoxycorticosterone (20 μM, containing 1.25 nCi of [4-14C]11-deoxycorticosterone in ethanol). Thereafter, the plate was stored at 37 °C. and 5% CO2 in a CO2 incubator. The V79 MZh 11B1 cells were incubated for 120 min, and the V79 MZh 11B2 cells were incubated for 40 min. Controls without inhibitor were treated in the same way. The enzyme reactions were quenched by extracting the supernatant with 500 μl of EtOAc. The samples were centrifuged (10,000 g, 2 min), the solvent was removed and evaporated. The residue was taken up in 10 μl of chloroform and analyzed by HPTLC (see below).
|
Homo sapiens
|
81.0
nM
|
|
Inhibition Assay: V79 MZh11B1 and V79 MZh 11B2 cells (8˙10^5 cells per well) were grown to confluency on 24-well cell culture plates with 1.9 cm^2 culture area per well (Nunc, Roskilde, Denmark). Before the test, the DMEM culture medium present was removed, and 450 μl of fresh DMEM with inhibitor was added for at least three concentrations to each well to determine the IC50. After preincubation (60 min, 37 °C.), the reaction was started by adding 50 μl of DMEM with 2.5 μl of solution of the substrate 11-deoxycorticosterone (20 μM, containing 1.25 nCi of [4-14C]11-deoxycorticosterone in ethanol). Thereafter, the plate was stored at 37 °C. and 5% CO2 in a CO2 incubator. The V79 MZh 11B1 cells were incubated for 120 min, and the V79 MZh 11B2 cells were incubated for 40 min. Controls without inhibitor were treated in the same way. The enzyme reactions were quenched by extracting the supernatant with 500 μl of EtOAc. The samples were centrifuged (10,000 g, 2 min), the solvent was removed and evaporated. The residue was taken up in 10 μl of chloroform and analyzed by HPTLC (see below).
|
Homo sapiens
|
81.0
nM
|
|
|
CYP17 Inhibition Assay: A solution of 6.25 nmol of progesterone (in 5 μl of MeOH) was dissolved in 140 μl of phosphate buffer (0.05 M; pH 7.4; 1 mM MgCl2; 0.1 mM EDTA and 0.1 mM DTT) and preincubated for 5 min at 37 °C. together with 50 μl of NADPH-regenerating system (phosphate buffer with 10 mM NADP®, 100 mM glucose-6-phosphate and 2,5 units of glucose-6-phosphate dehydrogenase) and inhibitor (in 5 μl of DMSO). Control incubations were performed in parallel with 5 μl DMSO without inhibitor. The reaction was started by adding 50 μl of a membrane suspension diluted 1 to 5 in phosphate buffer (0.8 to 1 mg of protein per ml). After thoroughly mixing the components, the mixture was incubated at 37 °C. for 30 min. The reaction was quenched by adding 50 μl of 1 N HCl. The steroids were extracted with 1 ml of EtOAc. After a centrifugation step (5 min at 2,500 g), 900 μl of the organic phase was transferred into an Eppendorf vessel with 250 μl of the incubation buffer and 50 μl of 1 N HCl and again shaken. After the centrifugation, 800 μl of the organic phase was removed, placed into a new vessel and evaporated to dryness. The samples were dissolved in 50 μl of a water-methanol mixture (1:1) and analyzed by HPLC.
|
Homo sapiens
|
80.5
nM
|
|
|
Cellular Inhibition Assay: V79MZ cells expressing human CYP11B1 and human CYP11B2 genes, respectively, were grown on 24-well cell culture plates (8×10^5 cells per well) with 1.9 cm^2 culture area per well in 1 ml DMEM culture medium until confluence. Before testing, the DMEM culture medium was removed and 450 μl of fresh DMEM, containing the inhibitor in at least three different concentrations for determining the IC50 value, was added to each well. Every value was determined at least three times. After a pre-incubation step of 60 min at 37° C., the reaction was started by the addition of 50 μl of DMEM containing the substrate 11-deoxycorticosterone (containing 0.15 μCi of [1,2-3H] 11-deoxycorticosterone, dissolved in ethanol, final concentration 100 nM). The V79MZh11B1 cells were incubated for 25 min, the V79MZh11B2 cells were incubated for 50 min. Controls were treated in the same way without inhibitors. The maximum DMSO concentration in each well was 1%. Enzyme reactions were stopped by extracting the supernatant with 500 μl ethyl acetate. Samples were centrifuged (10000×g, 2 min), and the solvent was pipetted into fresh cups. The solvent was evaporated and the steroids were redissolved in 40 μl of methanol and analyzed by HPLC using radioflow detection (Ehmer et al. J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179 and Denner et al. Endocr. Res. 1995, 21, 443-448).
|
Homo sapiens
|
127.0
nM
|
|
|
Cellular Inhibition Assay: V79MZ cells expressing human CYP11B1 and human CYP11B2 genes, respectively, were grown on 24-well cell culture plates (8×10^5 cells per well) with 1.9 cm^2 culture area per well in 1 ml DMEM culture medium until confluence. Before testing, the DMEM culture medium was removed and 450 μl of fresh DMEM, containing the inhibitor in at least three different concentrations for determining the IC50 value, was added to each well. Every value was determined at least three times. After a pre-incubation step of 60 min at 37° C., the reaction was started by the addition of 50 μl of DMEM containing the substrate 11-deoxycorticosterone (containing 0.15 μCi of [1,2-3H] 11-deoxycorticosterone, dissolved in ethanol, final concentration 100 nM). The V79MZh11B1 cells were incubated for 25 min, the V79MZh11B2 cells were incubated for 50 min. Controls were treated in the same way without inhibitors. The maximum DMSO concentration in each well was 1%. Enzyme reactions were stopped by extracting the supernatant with 500 μl ethyl acetate. Samples were centrifuged (10000×g, 2 min), and the solvent was pipetted into fresh cups. The solvent was evaporated and the steroids were redissolved in 40 μl of methanol and analyzed by HPLC using radioflow detection (Ehmer et al. J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179 and Denner et al. Endocr. Res. 1995, 21, 443-448).
|
Homo sapiens
|
67.0
nM
|
|
|
Inhibition of CYP3A4 using in human liver microsomes using midazolam as substrate after 5 to 15 mins
|
Homo sapiens
|
18.0
nM
|
|
|
Inhibition of CYP3A4 using in human liver microsomes using testosterone as substrate after 5 to 15 mins
|
Homo sapiens
|
15.0
nM
|
|
|
Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay
|
Rattus norvegicus
|
80.6
nM
|
|
|
Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay
|
Homo sapiens
|
200.0
nM
|
|
|
Inhibition of recombinant human CYP3A4 expressed in insect cells at >= 1 uM using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay relative to control
|
Homo sapiens
|
85.0
%
|
|
|
Inhibition of CYP3A4 (unknown origin) expressed in baculosomes
|
Homo sapiens
|
40.0
nM
|
|
|
Inhibition of N-terminal MBP-tagged human CYP24A1 expressed in Escherichia coli assessed as reduction in hydrolase activity incubated for 25 mins using Adx, AdR and 1,25(OH)2D3
|
Homo sapiens
|
500.0
nM
|
|
|
Inhibition of human CYP27B1 expressed in Escherichia coli assessed as reduction in hydrolase activity incubated for 25 mins using Adx, AdR and 1,25(OH)2D3
|
Homo sapiens
|
340.0
nM
|
|
|
Inhibition of MBP-tagged human CYP24A1 expressed Escherichia coli BL21-Gold(DE3) incubated for 25 mins in presence of Adx, AdR 1,25(OH)2D3 and NADPH by HPLC method
|
Homo sapiens
|
500.0
nM
|
|
|
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis
|
Homo sapiens
|
35.9
nM
|
|
|
Inhibition of CYP3A4 (unknown origin) by CYP3A4 P450-Glo assay
|
Homo sapiens
|
140.0
nM
|
|
|
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis
|
Homo sapiens
|
22.0
nM
|
|
|
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis
|
Homo sapiens
|
13.0
nM
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
87.05
%
|
|
|
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method
|
Homo sapiens
|
182.6
nM
|
|
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by XTT assay relative to control
|
Homo sapiens
|
40.0
%
|
|
|
Cytotoxicity against human HEK293T cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by XTT assay relative to control
|
Homo sapiens
|
40.0
%
|
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
17.52
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.16
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.16
%
|
|
